The present invention presents new and innovative methods and systems for personalized, real-time diet and lifestyle recommendations for users that are seeking to improve their own fertility. In a preferred embodiment, the present invention relates to novel methods and systems for personalized dietary recommendations for improving fertility in individuals, especially men, with prostate conditions.

An application of a compound using intra-cyclic peroxo-bridged sesquiterpenes as a parent nucleus in metabolism-related fatty liver diseases is provided. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus has the structure shown in Formula I, where A denotes O, —OH, OCH3, —OCH.sub.2CH.sub.3, or —OC.sub.4H.sub.5O.sub.3. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus is configured for preparing a drug or a composition for treating metabolism-related fatty liver diseases. The present invention demonstrates that the compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus can improve the function of mitochondria. in liver cells and enhance the fatty acid β-oxidation capacity thereof and can be used for the treatment of metabolic dysfunction due to mitochondrial dysfunction, as well as the resulting liver fat accumulation, inflammation, and fibrotic lesions.

An application of a compound using intra-cyclic peroxo-bridged sesquiterpenes as a parent nucleus in metabolism-related fatty liver diseases is provided. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus has the structure shown in Formula I, where A denotes O, —OH, OCH3, —OCH.sub.2CH.sub.3, or —OC.sub.4H.sub.5O.sub.3. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus is configured for preparing a drug or a composition for treating metabolism-related fatty liver diseases. The present invention demonstrates that the compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus can improve the function of mitochondria. in liver cells and enhance the fatty acid β-oxidation capacity thereof and can be used for the treatment of metabolic dysfunction due to mitochondrial dysfunction, as well as the resulting liver fat accumulation, inflammation, and fibrotic lesions.

The present invention is directed to a personal composition comprising a) a strobilurin; b) salicylic acid wherein the ratio of a:b is from about 1:1 to about 100:1; wherein there is a synergistic anti-inflammatory/cellular stress activity.

The present invention is directed to a personal composition comprising a) a strobilurin; b) salicylic acid wherein the ratio of a:b is from about 1:1 to about 100:1; wherein there is a synergistic anti-inflammatory/cellular stress activity.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The invention relates to the field of inhalation methods and inhalation devices for liquids. In particular, the invention relates to an inhalation method using an inhalation device adapted to separately eject at least two liquid compositions each having different properties, and to a method for the generation of an aerosol of at least two medicinal formulations by means of such inhalation device.

The invention relates to the field of inhalation methods and inhalation devices for liquids. In particular, the invention relates to an inhalation method using an inhalation device adapted to separately eject at least two liquid compositions each having different properties, and to a method for the generation of an aerosol of at least two medicinal formulations by means of such inhalation device.

The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and/or co-stimulated by pre- and/or co-incubation with said transduction enhancing compound or a combination of transduction enhancing compounds prior to and/or during contacting the target cell with the retroviral vector.